- Clinical Trials
- June 2024
- 60 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1193EUR$1,250USD£1,000GBP
- Report
- June 2024
- 200 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Drug Pipelines
- July 2023
- 30 Pages
Global
From €2625EUR$2,750USD£2,199GBP
- Drug Pipelines
- February 2022
- 76 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Report
- April 2023
- 147 Pages
Global
From €4723EUR$4,949USD£3,957GBP
Hyperoxaluria is a disorder of the liver and kidneys caused by an excess of oxalate in the body. It is typically treated with drugs that reduce the amount of oxalate produced by the body, or that increase the amount of oxalate excreted in the urine. These drugs are used to reduce the risk of kidney stones, kidney damage, and other complications associated with hyperoxaluria. Common drugs used to treat hyperoxaluria include allopurinol, pyridoxine, and calcium citrate.
The hyperoxaluria drug market is a niche market, with a limited number of drugs available to treat the disorder. The market is expected to grow in the coming years, as more drugs are developed to treat hyperoxaluria and its associated complications.
Some companies in the hyperoxaluria drug market include Pfizer, Merck, and Sanofi. Show Less Read more